ALDARA Drug Patent Profile

When do Aldara patents expire, and what generic alternatives are available?

Aldara is a drug marketed by Bausch and is included in one NDA.

The generic ingredient in ALDARA is imiquimod. There are fourteen drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the imiquimod profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Aldara

A generic version of ALDARA was approved as imiquimod by FOUGERA PHARMS on February 25^th, 2010.

Summary for ALDARA

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	67
Patent Applications:	1,393
Drug Prices:	Drug price information for ALDARA
What excipients (inactive ingredients) are in ALDARA?	ALDARA excipients list
DailyMed Link:	ALDARA at DailyMed

See drug prices for ALDARA

Recent Clinical Trials for ALDARA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Leiden University Medical Center	Early Phase 1
German Cancer Aid	Phase 1
Roche Pharma AG	Phase 1

See all ALDARA clinical trials

Paragraph IV (Patent) Challenges for ALDARA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ALDARA	Cream	imiquimod	5%	020723	1	2006-10-17

US Patents and Regulatory Information for ALDARA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch	ALDARA	imiquimod	CREAM;TOPICAL	020723-001	Feb 27, 1997		DISCN	Yes	No

EU/EMA Drug Approvals for ALDARA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Viatris Healthcare Limited	Aldara	imiquimod	EMEA/H/C/000179Imiquimod cream is indicated for the topical treatment of :External genital and perianal warts (condylomata acuminata) in adults.Small superficial basal cell carcinomas (sBCCs) in adults.Clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses (AKs) on the face or scalp in immunocompetent adult patients when size or number of lesions limit the efficacy and/or acceptability of cryotherapy and other topical treatment options are contraindicated or less appropriate.	Authorised	no	no	no	1998-09-18
Viatris Healthcare Limited	Zyclara	imiquimod	EMEA/H/C/002387Zyclara is indicated for the topical treatment of clinically typical, non-hyperkeratotic, non-hypertrophic, visible or palpable actinic keratosis of the full face or balding scalp in immunocompetent adults when other topical treatment options are contraindicated or less appropriate.	Authorised	no	no	no	2012-08-23
Laboratoires 3M Santé	Zartra	imiquimod	EMEA/H/C/000180Imiquimod cream is indicated for the topical treatment of external genital and perianal warts (condyloma acuminata) in adult patients.	Withdrawn	no	no	no	1998-09-18

International Patents for ALDARA

See the table below for patents covering ALDARA around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2004597	FORMULES TOPIQUES ET SYSTEMES DE DISPENSATION TRANSDERMIQUE CONTENANT DE LA 1-ISOBUTYL-1H-IMIDAZO [4,5-C]QUINOLINE-4-AMINE (TOPICAL FORMULATIONS AND TRANSDERMAL DELIVERY SYSTEMS CONTAINING 1-ISOBUTYL-1H-IMIDAZO-[4,5-C]QUINOLINE-4-AMINE)
European Patent Office	0376534	Compositions à utilisation topique et systèmes pour l'administration transdermale contenant la 1-isobutyl-1H-imidazo[4,5-c]quinoline-4-amine. (Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinoline-4-amine.)
Japan	S60123488	1H-IMIDAZO(4,5-C)QUINOLINES AND 1H-IMIDAZO(4,5-C)QUINOLINE-4-AMINES

Supplementary Protection Certificates for ALDARA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0145340	99C0005	Belgium		PRODUCT NAME: FOSPHENYTOIN DISODIUM; NAT. REGISTRATION NO/DATE: NL 23 613 19980806; FIRST REGISTRATION: GB - PL 000 19/0157 19980204
0145340	SPC/GB99/003	United Kingdom		PRODUCT NAME: IMIQUIMOD; REGISTERED: UK EU/1/98/080/001 19980918

Last updated: February 11, 2026

What Are the Market Dynamics for ALDARA (Imiquimod)?

ALDARA (imiquimod) is a topical immune response modifier approved by the FDA for treating actinic keratosis, superficial basal cell carcinoma, and genital warts. Market factors influencing its trajectory include patent status, competitive landscape, regulatory environment, and emerging treatment options.

Patent and Market Exclusivity

• The original patent for ALDARA expired in the U.S. in 2017, opening the door for generic competition.
• Despite patent expiration, the branded product retained market share through proprietary formulation patents and shell branding strategies.
• Patent litigations and patent term extensions have delayed generic entry until recent years, with generic imiquimod launched broadly by 2020.

Competitive Landscape

• Several generics now compete in the marketplace, often at significantly lower price points.
• Other treatments for actinic keratosis include fluorouracil, diclofenac, and photodynamic therapy.
• For genital warts, treatment alternatives include podofilox, sinecatechins, and surgical removal.

Regulatory and Reimbursement Factors

• Reimbursement depends on regional health policies, with insurer coverage favoring lower-cost generics.
• Ongoing clinical trials exploring new indications or formulations could influence usage patterns.

Market Size and Segments

Segment	Market Size (2022)	Growth Rate (CAGR 2023-2028)	Notes
Actinic Keratosis	$1.2 billion	4.5%	Largest segment; driven by aging populations
Superficial Basal Cell	$350 million	3.8%	Niche but stable; recurrence management
Genital Warts	$300 million	2.7%	Competitive with multiple topical and procedural options

Recent Market Trends

• Post-patent expiry, unit sales declined initially due to generic competition but have stabilized as formulations with extended patents are marketed.
• Adoption of ALDARA in combination therapy and off-label uses is limited but emerging.
• The COVID-19 pandemic impacted distribution, but recovery is underway.

What Is the Financial Trajectory for ALDARA?

Revenue and Sales Trends

• In 2022, U.S. sales of ALDARA branded product approximate $50 million.
• Generic imiquimod sales have risen sharply since 2020, capturing roughly $150 million annually in the U.S.
• Total imiquimod market revenue in the U.S. reached roughly $200 million in 2022, down from peak branded sales of over $300 million in 2016.

Impact of Patent Expiry and Generics

• Patent expiration in 2017 allowed immediate entry of generics, causing a 50% decrease in branded sales over the subsequent two years.
• Branded sales stabilized at approximately $50 million, representing about 25% of the market share.
• The rise of multiple generic manufacturers eroded the market share of the original brand.

Cost and Pricing Dynamics

• The average wholesale price (AWP) for branded ALDARA was approximately $700 per tube in 2016.
• Generic imiquimod products are priced around $200 to $300 per tube.
• Pricing compression has led to reduced revenue per unit but has increased overall market volume.

R&D and Pipeline Outlook

• No recent FDA approvals for new formulations or indications have been announced.
• Pharmaceutical companies are exploring combination therapies and novel delivery systems but remain in early-stage development.
• Potential pipeline products could sustain demand if approved for new dermatological or oncological indications.

Investment and Commercial Strategy

• Companies maintain direct sales efforts for niche markets like genital warts and actinic keratosis.
• Focus on expanding access via reimbursement negotiations and cost-effective packaging.
• Strategies include licensing deals, partnering with dermatology clinics, and expanding into emerging markets.

Key Market Dynamics Summary

• Patent expiration in 2017 increased generic market share but left room for branded offerings with patent extensions.
• Generic competition drives lower prices, reduces branded sales, and alters profit margins.
• Market segments show variable growth; actinic keratosis remains the largest driver.
• Pricing dynamics favor generics, leading to decreased revenue per unit for the brand.
• Pipeline development remains limited; current revenue relies mainly on existing indications.

Key Financial Outlook Summary

• 2022 total imiquimod revenue in the U.S. is approximately $200 million.
• Branded ALDARA's share declined to about 12.5% of the total market, with sales around $25 million.
• Future revenue depends heavily on generic uptake, pricing pressures, and potential new indications.
• The lack of recent innovation constrains growth prospects unless new formulations receive approval.

Key Takeaways

• ALDARA's market has transitioned from dominance to a competitive, price-sensitive environment following patent expiration.
• Generic versions account for a substantial share; revenues are declining.
• The pipeline for new uses or formulations remains limited, constraining potential growth.
• Market segments like actinic keratosis still provide opportunity but face competition from other therapies.
• Management strategies focus on cost containment, access expansion, and exploring new indications.

FAQs

1. When did ALDARA lose its patent protection?
The primary patent expired in 2017, leading to broad generic entry by 2020.

2. What are the main competitors to ALDARA?
Generic imiquimod, fluorouracil, diclofenac gel, and photodynamic therapy.

3. How has the revenue changed since patent expiry?
Branded sales declined from over $300 million in 2016 to approximately $50 million in 2022; total imiquimod market revenue in the U.S. is around $200 million.

4. What is the outlook for ALDARA's pipeline or new indications?
No significant pipeline developments are public; growth depends on sustaining existing indications and exploring off-label uses.

5. How do reimbursement policies affect ALDARA?
Lower-cost generics are favored by payers, leading to reduced revenue for the brand, especially after patent expiry.

References

1. IQVIA. (2022). Market Reports on Dermatology Therapeutics.
2. U.S. Food and Drug Administration. (2017). Orange Book — Patent and exclusivity data.
3. Evaluate Pharma. (2022). Oncology and dermatology market forecasts.
4. Company filings and earnings reports, 2022.
5. MarketWatch. (2023). Dermatology drug market analysis.